vs

Side-by-side financial comparison of Epsilon Energy Ltd. (EPSN) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.

ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $14.8M, roughly 1.9× Epsilon Energy Ltd.). Epsilon Energy Ltd. runs the higher net margin — -83.9% vs -147.1%, a 63.2% gap on every dollar of revenue. On growth, Epsilon Energy Ltd. posted the faster year-over-year revenue change (65.7% vs -67.6%).

Epsilon Composite is a French company created in 1987 by Stephane LULL, its current CEO. The company was founded in January 1987. Its production site is located in Gaillan, France. Stéphane Lull is the CEO.

ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.

EPSN vs SPRY — Head-to-Head

Bigger by revenue
SPRY
SPRY
1.9× larger
SPRY
$28.1M
$14.8M
EPSN
Growing faster (revenue YoY)
EPSN
EPSN
+133.3% gap
EPSN
65.7%
-67.6%
SPRY
Higher net margin
EPSN
EPSN
63.2% more per $
EPSN
-83.9%
-147.1%
SPRY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EPSN
EPSN
SPRY
SPRY
Revenue
$14.8M
$28.1M
Net Profit
$-12.4M
$-41.3M
Gross Margin
Operating Margin
-129.0%
-147.6%
Net Margin
-83.9%
-147.1%
Revenue YoY
65.7%
-67.6%
Net Profit YoY
-1535.0%
-182.8%
EPS (diluted)
$-0.55
$-0.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EPSN
EPSN
SPRY
SPRY
Q4 25
$14.8M
$28.1M
Q3 25
$9.0M
$32.5M
Q2 25
$11.6M
$15.7M
Q1 25
$16.2M
$8.0M
Q4 24
$8.9M
$86.6M
Q3 24
$7.3M
$2.1M
Q2 24
$7.3M
$500.0K
Q1 24
$8.0M
$0
Net Profit
EPSN
EPSN
SPRY
SPRY
Q4 25
$-12.4M
$-41.3M
Q3 25
$1.1M
$-51.2M
Q2 25
$1.6M
$-44.9M
Q1 25
$4.0M
$-33.9M
Q4 24
$-760.8K
$49.9M
Q3 24
$366.0K
$-19.1M
Q2 24
$815.7K
$-12.5M
Q1 24
$1.5M
$-10.3M
Operating Margin
EPSN
EPSN
SPRY
SPRY
Q4 25
-129.0%
-147.6%
Q3 25
6.7%
-163.7%
Q2 25
7.1%
-302.9%
Q1 25
44.3%
-466.3%
Q4 24
6.8%
54.5%
Q3 24
3.3%
-1051.6%
Q2 24
16.0%
-3068.0%
Q1 24
17.6%
Net Margin
EPSN
EPSN
SPRY
SPRY
Q4 25
-83.9%
-147.1%
Q3 25
11.9%
-157.4%
Q2 25
13.3%
-285.6%
Q1 25
24.8%
-425.7%
Q4 24
-8.5%
57.7%
Q3 24
5.0%
-925.0%
Q2 24
11.2%
-2503.2%
Q1 24
18.9%
EPS (diluted)
EPSN
EPSN
SPRY
SPRY
Q4 25
$-0.55
$-0.41
Q3 25
$0.05
$-0.52
Q2 25
$0.07
$-0.46
Q1 25
$0.18
$-0.35
Q4 24
$-0.04
$0.52
Q3 24
$0.02
$-0.20
Q2 24
$0.04
$-0.13
Q1 24
$0.07
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EPSN
EPSN
SPRY
SPRY
Cash + ST InvestmentsLiquidity on hand
$9.0M
$245.0M
Total DebtLower is stronger
$96.4M
Stockholders' EquityBook value
$124.7M
$114.3M
Total Assets
$228.2M
$327.7M
Debt / EquityLower = less leverage
0.84×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EPSN
EPSN
SPRY
SPRY
Q4 25
$9.0M
$245.0M
Q3 25
$12.8M
$288.2M
Q2 25
$9.9M
$240.1M
Q1 25
$6.9M
$275.7M
Q4 24
$6.5M
$314.0M
Q3 24
$8.3M
$204.6M
Q2 24
$8.6M
$218.7M
Q1 24
$2.3M
$223.6M
Total Debt
EPSN
EPSN
SPRY
SPRY
Q4 25
$96.4M
Q3 25
$96.2M
Q2 25
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
EPSN
EPSN
SPRY
SPRY
Q4 25
$124.7M
$114.3M
Q3 25
$100.2M
$147.7M
Q2 25
$100.2M
$192.3M
Q1 25
$99.7M
$229.0M
Q4 24
$96.7M
$256.8M
Q3 24
$98.4M
$201.0M
Q2 24
$99.6M
$215.2M
Q1 24
$99.9M
$223.9M
Total Assets
EPSN
EPSN
SPRY
SPRY
Q4 25
$228.2M
$327.7M
Q3 25
$126.3M
$372.8M
Q2 25
$123.6M
$313.5M
Q1 25
$125.5M
$327.3M
Q4 24
$120.5M
$351.2M
Q3 24
$121.8M
$217.6M
Q2 24
$121.1M
$222.0M
Q1 24
$125.1M
$227.6M
Debt / Equity
EPSN
EPSN
SPRY
SPRY
Q4 25
0.84×
Q3 25
0.65×
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EPSN
EPSN
SPRY
SPRY
Operating Cash FlowLast quarter
$-277.0K
$-43.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EPSN
EPSN
SPRY
SPRY
Q4 25
$-277.0K
$-43.5M
Q3 25
$4.0M
$-47.0M
Q2 25
$8.3M
$-39.6M
Q1 25
$8.6M
$-40.7M
Q4 24
$5.0M
$42.0M
Q3 24
$2.7M
$-14.5M
Q2 24
$5.4M
$-7.3M
Q1 24
$3.7M
$-6.7M
Free Cash Flow
EPSN
EPSN
SPRY
SPRY
Q4 25
Q3 25
$-47.2M
Q2 25
$-39.6M
Q1 25
$-40.8M
Q4 24
$41.7M
Q3 24
$-14.6M
Q2 24
$-7.3M
Q1 24
$-6.8M
FCF Margin
EPSN
EPSN
SPRY
SPRY
Q4 25
Q3 25
-145.4%
Q2 25
-252.2%
Q1 25
-512.1%
Q4 24
48.2%
Q3 24
-706.3%
Q2 24
-1463.4%
Q1 24
Capex Intensity
EPSN
EPSN
SPRY
SPRY
Q4 25
0.0%
Q3 25
0.6%
Q2 25
0.3%
Q1 25
1.1%
Q4 24
0.3%
Q3 24
6.8%
Q2 24
7.6%
Q1 24
Cash Conversion
EPSN
EPSN
SPRY
SPRY
Q4 25
Q3 25
3.70×
Q2 25
5.38×
Q1 25
2.14×
Q4 24
0.84×
Q3 24
7.50×
Q2 24
6.60×
Q1 24
2.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EPSN
EPSN

Gas Oil Ngls And Condensate$13.3M90%
Gas Gathering And Compression$1.5M10%

SPRY
SPRY

Products$20.3M72%
Other$7.8M28%

Related Comparisons